 |
|
Fluocinolone Acetonide for the Treatment of UveitisWeighing the Balance Between Local and Systemic Immunosuppression
Steven Yeh, MD;
Robert B. Nussenblatt, MD, MPH
Arch Ophthalmol. 2008;126(9):1287-1289.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The increasingly complex array of local and systemic immunosuppressive options available to ophthalmologists caring for patients with ocular inflammatory diseases requires thoughtful consideration of the risks and benefits associated with the introduction of each novel therapy. In this issue of the Archives, Callanan et al1 report the long-term results of a large cohort of patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant and present their appraisal of this medication. Their study contributes greatly to our understanding of the potential benefits of this local corticosteroid delivery system, and their discussion of reported complications is critical for patient counseling and risk assessment when considering the precise role of this therapy for patient care.
Jaffe et al2 initially reported encouraging results on the efficacy of the FA implant for uveitis in a 34-week prospective, historically controlled, multicenter trial in 278 patients . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Treatment of Posterior Uveitis With a Fluocinolone Acetonide Implant: Three-Year Clinical Trial Results
David G. Callanan, Glenn J. Jaffe, Daniel F. Martin, P. Andrew Pearson, and Timothy L. Comstock
Arch Ophthalmol. 2008;126(9):1191-1201.
ABSTRACT
| FULL TEXT
|
